New Pancreatic Cancer Drug Doubles Survival Rate
An international trial presented at the American Society of Clinical Oncology congress revealed that a new drug, daraxonrasib, significantly increases survival rates for patients with metastatic pancreatic tumors, with France also rolling out a prevention program.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (32/100)Sources
Pancreatic cancers: New drug doubles survival rate as France rolls out prevention program
In cases of metastatic pancreatic tumors, daraxonrasib has been shown to drastically increase survival rates, according to an international trial presented at the American Society of Clinical Oncology congress on Sunday. In France, a personalized screening and prevention program, launched by the Gustave-Roussy Institute has been extended to eight additional centers.
Read full article →Revolution’s pancreatic cancer drug doubles survival, boosts quality of life - Daily Mirror - Sri Lanka
Revolution’s pancreatic cancer drug doubles survival, boosts quality of life Daily Mirror - Sri Lanka
Read full article →
